Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial carbohydrate transporters and metabolic enzymes in the gut microbiota represent a complex network of proteins responsible for the breakdown and uptake of complex dietary polysaccharides that human enzymes cannot digest (Lombard et al., 2014). This group includes glycoside hydrolases, polysaccharide lyases, and carbohydrate esterases, often organized into Polysaccharide Utilization Loci (PULs), as well as specialized transport systems like the Phosphotransferase System (PTS) and ABC transporters (Grondin et al., 2017). By fermenting these carbohydrates, the microbiota produces short-chain fatty acids (SCFAs) such as butyrate and propionate, which are crucial for host energy homeostasis and immune regulation (Koh et al., 2016). Dysregulation of these metabolic pathways is linked to various conditions, including obesity, type 2 diabetes, and inflammatory bowel disease (Turnbaugh et al., 2006). Therapeutic strategies targeting these enzymes and transporters aim to modulate the gut environment, either through small-molecule inhibitors like acarbose or through the use of prebiotics that selectively favor beneficial bacterial taxa (DiNicolantonio et al., 2015). Understanding the specificity of these bacterial targets is essential for developing precision microbiome-based therapies that minimize off-target effects on the host or beneficial commensal species.
Modulation of gut microbiota metabolic activity through the inhibition of bacterial glycoside hydrolases or the selective substrate provision to transporters, resulting in altered production of short-chain fatty acids and improved host glycemic control.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial carbohydrate transporters and metabolic enzymes in gut microbiota.